Historique
Périodique
Combination treatment for nicotine dependence: state of the science
(Combiner substituts nicotiniques et antidépresseurs ou pharmacothérapie et thérapie comportementale pour le traitement de la dépendance à la nicotine : l'état de la recherche)
Auteur(s) :
K. S. INGERSOLL ;
J. COHEN
Article en page(s) :
1923-1943
Refs biblio. :
66
Domaine :
Tabac / Tobacco / e-cigarette
Langue(s) :
Anglais
Thésaurus mots-clés
TABAC
;
NICOTINE
;
DEPENDANCE
;
TRAITEMENT
;
PHARMACOTHERAPIE
;
THERAPIE COMPORTEMENTALE
;
ANTIDEPRESSEURS
;
SUBSTITUTS NICOTINIQUES
Note générale :
Substance Use and Misuse, 2005, 40, (13-14), 1923-1943
Note de contenu :
tabl.
Résumé :
ENGLISH :
Both nicotine replacement and sustained-release buproprion double the odds of achieving short- and moderate-term abstinence from nicotine. However, questions remain about the efficacy of combining pharmacotherapies. Our purposes were to review the evidence for (1) combined pharmacotherapy and (2) multimodal treatment combining pharmacotherapy and behavioral treatment and to recommend combinations of treatments to reduce nicotine dependence. Combining first-line pharmacotherapies with each other or with investigational drugs shows little benefet. In contrast, trials combining specific behavioral treatments with first-line pharmacotherapies show enhanced smoking cessation rates, but benefits are not seen in all populations. We recommend future directions for research, including better specification of behavioral components and further examination of the length and timing of treatment. (Editor's abstract.)
ENGLISH :
Both nicotine replacement and sustained-release buproprion double the odds of achieving short- and moderate-term abstinence from nicotine. However, questions remain about the efficacy of combining pharmacotherapies. Our purposes were to review the evidence for (1) combined pharmacotherapy and (2) multimodal treatment combining pharmacotherapy and behavioral treatment and to recommend combinations of treatments to reduce nicotine dependence. Combining first-line pharmacotherapies with each other or with investigational drugs shows little benefet. In contrast, trials combining specific behavioral treatments with first-line pharmacotherapies show enhanced smoking cessation rates, but benefits are not seen in all populations. We recommend future directions for research, including better specification of behavioral components and further examination of the length and timing of treatment. (Editor's abstract.)
Affiliation :
Department of Psychiatry Medicine, University of Virginia, Charlottesville, VA 22908. E-mail : kareningersollgmail.com
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |